ストックスクリーナーアプリを入手
7.59
2.32%
-0.18
アフターアワーズ：
7.59
前日終値:
$7.77
開ける：
$7.61
24時間の取引高:
206.05K
Relative Volume:
0.71
時価総額：
$395.27M
収益：
-
当期純損益:
$-31.93M
株価収益率:
-10.58
EPS:
-0.7173
ネットキャッシュフロー:
$-27.71M
1週間 パフォーマンス:
-7.78%
1か月 パフォーマンス:
+0.66%
6か月 パフォーマンス:
+23.62%
1年 パフォーマンス:
+24.84%
1日の値動き範囲:
$7.50
$7.85
1週間の範囲:
$7.32
$8.275
52週間の値動き範囲:
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
7.59 | 404.64M | 0 | -31.93M | -27.71M | -0.7173 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-14 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 開始されました | TD Cowen | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
Market Review: Is DiaMedica Therapeutics Inc a strong growth stockJuly 2025 Price Swings & Consistent Income Trade Recommendations - baoquankhu1.vn
DiaMedica (DMAC) Gains Health Canada Approval for Preeclampsia T - GuruFocus
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - The AI Journal
DiaMedica Therapeutics receives Health Canada clearance to initiate phase 2 study of DM199 in preeclampsia - marketscreener.com
Corient IA LLC Acquires New Holdings in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Risk Analysis: Can DiaMedica Therapeutics Inc lead its sector in growthPortfolio Value Summary & Fast Momentum Entry Tips - baoquankhu1.vn
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.1%Time to Sell? - MarketBeat
Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight - Yahoo Finance UK
Rate Cut: Is DiaMedica Therapeutics Inc stock a top performer YTDJuly 2025 Price Swings & Daily Market Momentum Tracking - baoquankhu1.vn
Earnings Recap: Can DiaMedica Therapeutics Inc keep up with sector leadersGold Moves & Consistent Profit Trading Strategies - baoquankhu1.vn
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
DMAC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Recap: How does DiaMedica Therapeutics Inc compare to its peersJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
How DiaMedica Therapeutics Inc. stock trades before earningsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - mfd.ru
Leon Cooperman discloses 6.6% DiaMedica (DMAC) holding - Stock Titan
Trading Recap: Is FURY a play on infrastructure spendingWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn
DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their Holdings - Yahoo Finance
Is DiaMedica Therapeutics Inc a cyclical or defensive stockAnalyst Downgrade & Technical Confirmation Trade Alerts - baoquankhu1.vn
DMAC Technical Analysis & Stock Price Forecast - Intellectia AI
Swing Trade: Can DiaMedica Therapeutics Inc keep up with sector leadersTrade Signal Summary & Community Supported Trade Ideas - baoquankhu1.vn
Is DiaMedica Therapeutics Inc. stock a top performer YTDJuly 2025 Volume & AI Enhanced Trading Alerts - mfd.ru
Highs Report: How does DiaMedica Therapeutics Inc compare to its peersChart Signals & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Strengthens Balance Sheet With $12.2 Million Capital Raise While Advancing Preeclampsia Program - Longbridge
Dividend Watch: Can DiaMedica Therapeutics Inc. keep up with sector leaders2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares - simplywall.st
Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock - Investing.com
Aug Final Week: Whats next for CWAN stockJuly 2025 Update & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
What technical charts say about DiaMedica Therapeutics Inc. stock2025 Volume Leaders & Free Expert Approved Momentum Trade Ideas - bollywoodhelpline.com
Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8% - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
DiaMedica Therapeutics raises capital via share offering - MSN
Trading Action: Why DiaMedica Therapeutics Inc. stock is a value investor pickWeekly Profit Analysis & Low Risk Entry Point Tips - Bộ Nội Vụ
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nasdaq Moves: Is DiaMedica Therapeutics Inc a cyclical or defensive stockMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Panic Selling: Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideQuarterly Portfolio Summary & Safe Entry Momentum Stock Tips - Улправда
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.3%Should You Sell? - MarketBeat
Why DiaMedica Therapeutics Inc. stock is a value investor pickRecession Risk & Daily Technical Forecast Reports - ulpravda.ru
DiaMedica Therapeutics Raises Capital via Share Offering - The Globe and Mail
DiaMedica Therapeutics (DMAC) Seen as Strong Performer with Upco - GuruFocus
DiaMedica Therapeutics Inc.Common Stock (NQ: DMAC - FinancialContent
DiaMedica Therapeutics sells 1.5 million shares in $12.2 million block trade By Investing.com - Investing.com Nigeria
DiaMedica Therapeutics sells 1.5 million shares in $12.2 million block trade - Investing.com
A US$59m Drop in the Market Cap of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Is Not What Insiders Like to See After Purchasing Shares Recently - 富途牛牛
DiaMedica Therapeutics (DMAC) price target increased by 25.68% to 15.81 - MSN
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
Diamedica Therapeutics Inc (DMAC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Aug 25 '25 |
Buy |
6.00 |
338,265 |
2,029,252 |
7,654,045 |
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):